MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$20,029K
Free Cash flow
-$19,760K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Stock-based compensation expense
Prepaid expenses and other asset...
Accrued liabilities and other li...
Others
Negative Cash Flow Breakdown
Net loss
Payments of issuance cost and un...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-27,638
-26,237
-16,182
-14,181
Stock-based compensation expense
3,554
2,824
1,946
2,189
Depreciation
184
184
157
504
Non-cash research and development license expense
-
-
0
0
Non-cashinterest expense related to term loan
165
206
175
192
Non-cashlease expense
203
200
197
195
Loss on disposal of assets
0
-9
0
-114
Change in other, net
130
116
91
112
Loss on extinguishment of debt
0
0
0
0
Prepaid expenses and other assets
-1,778
4,130
-656
-628
Accounts payable
652
1,490
-297
461
Accrued liabilities and other liabilities
1,212
-1,753
1,741
208
Net cash used in operating activities
-19,760
-27,091
-11,516
-9,918
Capital expenditures
0
556
0
0
Net cash used in investing activities
0
-556
0
0
Proceeds from sale of common stock and pre-funded warrants in 2026 private placement
0
120,000
50,000
-
Payments from sale of common stock and pre-funded warrants in 2026 private placement
-
4,875
167
-
Proceeds from issuance of common stock from initial public offering
-
-
0
0
Payments of issuance cost and underwriting fees related to the sale of common stock and pre-funded warrants in 2026 private placement
5,223
-
-
-
Payments of issuance costs-IPO
-
-
0
0
Payment of withholding taxes for stock-based compensation
0
190
-
-
Payments on issuance cost from registration statement
0
0
0
0
Proceeds from issuance of term loan, net
0
0
0
0
Repayment of former term loan
0
0
0
0
Payment of loan financing cost
0
0
0
0
Payments on issuance costs-Series CPreferred Stock Financing
-
-
-
0
Payments of issuance costs-Series BAnd Series CPreferred Stock
-
-
0
-
Proceeds from exercise of stock options
75
6
352
153
Proceeds from convertible grant agreement
0
-
0
0
Net cash provided by financing activities
-273
114,941
50,185
153
Effect of exchange rate changes on cash, cash equivalents and restricted cash
4
-16
-1
-4
Net (decrease) increase in cash, cash equivalents and restricted cash
-20,029
87,278
38,668
-9,769
Cash, cash equivalents and restricted cash at the beginning of the period
264,262
176,984
138,316
168,729
Cash, cash equivalents and restricted cash at the end of the period
244,233
264,262
176,984
138,316
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Effect of exchange rate
changes on cash, cash...
$4K
(116.00%↑ Y/Y)
Net (decrease)
increase in cash, cash...
-$20,029K
(2.98%↑ Y/Y)
Canceled cashflow
$4K
Stock-based compensation
expense
$3,554K
(-10.55%↓ Y/Y)
Prepaid expenses and
other assets
-$1,778K
(-250.30%↓ Y/Y)
Accrued liabilities and
other liabilities
$1,212K
(154.16%↑ Y/Y)
Accounts payable
$652K
(1043.86%↑ Y/Y)
Non-cashlease expense
$203K
(-46.86%↓ Y/Y)
Depreciation
$184K
Non-cashinterest expense related
to term loan
$165K
(-54.42%↓ Y/Y)
Change in other, net
$130K
(4.84%↑ Y/Y)
something is missing
$4,875K
Proceeds from exercise of
stock options
$75K
(-62.12%↓ Y/Y)
Net cash used in
operating activities
-$19,760K
(34.86%↑ Y/Y)
Net cash provided by
financing activities
-$273K
(-102.80%↓ Y/Y)
Canceled cashflow
$7,878K
Canceled cashflow
$4,950K
Net loss
-$27,638K
(15.93%↑ Y/Y)
Payments of issuance cost
and underwriting...
$5,223K
Buy us a coffee
Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience, Inc. (ANRO)